Visual side effects associated with erectile dysfunction agents

Frederick W. Fraunfelder

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

PURPOSE: To describe the known ocular side effects of agents used to treat erectile dysfunction. DESIGN: Retrospective observational case series and literature review. METHODS: We reviewed 892 case reports from the National Registry of Drug-Induced Ocular Side Effects (Casey Eye Institute, Portland, Oregon), the Food and Drug Administration (FDA), and the World Health Organization (WHO) and conducted a comprehensive review of the literature. RESULTS: Ocular side effects of these drugs appear fully reversible and transitory. CONCLUSIONS: To date, evidence does not exist to discourage use of erectile dysfunction agents attributable to harmful ocular side effects. Ischemic optic neuropathy (ION) is "possible" by WHO classification, however, conclusive evidence linking ION to erectile dysfunction medications is still lacking.

Original languageEnglish (US)
Pages (from-to)723-724
Number of pages2
JournalAmerican Journal of Ophthalmology
Volume140
Issue number4
DOIs
StatePublished - Oct 2005

Fingerprint

Erectile Dysfunction
Ischemic Optic Neuropathy
United States Food and Drug Administration
Drug-Related Side Effects and Adverse Reactions
Registries
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Visual side effects associated with erectile dysfunction agents. / Fraunfelder, Frederick W.

In: American Journal of Ophthalmology, Vol. 140, No. 4, 10.2005, p. 723-724.

Research output: Contribution to journalArticle

Fraunfelder, Frederick W. / Visual side effects associated with erectile dysfunction agents. In: American Journal of Ophthalmology. 2005 ; Vol. 140, No. 4. pp. 723-724.
@article{2186176da84144e78c12c494ab3258cf,
title = "Visual side effects associated with erectile dysfunction agents",
abstract = "PURPOSE: To describe the known ocular side effects of agents used to treat erectile dysfunction. DESIGN: Retrospective observational case series and literature review. METHODS: We reviewed 892 case reports from the National Registry of Drug-Induced Ocular Side Effects (Casey Eye Institute, Portland, Oregon), the Food and Drug Administration (FDA), and the World Health Organization (WHO) and conducted a comprehensive review of the literature. RESULTS: Ocular side effects of these drugs appear fully reversible and transitory. CONCLUSIONS: To date, evidence does not exist to discourage use of erectile dysfunction agents attributable to harmful ocular side effects. Ischemic optic neuropathy (ION) is {"}possible{"} by WHO classification, however, conclusive evidence linking ION to erectile dysfunction medications is still lacking.",
author = "Fraunfelder, {Frederick W.}",
year = "2005",
month = "10",
doi = "10.1016/j.ajo.2005.02.049",
language = "English (US)",
volume = "140",
pages = "723--724",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Visual side effects associated with erectile dysfunction agents

AU - Fraunfelder, Frederick W.

PY - 2005/10

Y1 - 2005/10

N2 - PURPOSE: To describe the known ocular side effects of agents used to treat erectile dysfunction. DESIGN: Retrospective observational case series and literature review. METHODS: We reviewed 892 case reports from the National Registry of Drug-Induced Ocular Side Effects (Casey Eye Institute, Portland, Oregon), the Food and Drug Administration (FDA), and the World Health Organization (WHO) and conducted a comprehensive review of the literature. RESULTS: Ocular side effects of these drugs appear fully reversible and transitory. CONCLUSIONS: To date, evidence does not exist to discourage use of erectile dysfunction agents attributable to harmful ocular side effects. Ischemic optic neuropathy (ION) is "possible" by WHO classification, however, conclusive evidence linking ION to erectile dysfunction medications is still lacking.

AB - PURPOSE: To describe the known ocular side effects of agents used to treat erectile dysfunction. DESIGN: Retrospective observational case series and literature review. METHODS: We reviewed 892 case reports from the National Registry of Drug-Induced Ocular Side Effects (Casey Eye Institute, Portland, Oregon), the Food and Drug Administration (FDA), and the World Health Organization (WHO) and conducted a comprehensive review of the literature. RESULTS: Ocular side effects of these drugs appear fully reversible and transitory. CONCLUSIONS: To date, evidence does not exist to discourage use of erectile dysfunction agents attributable to harmful ocular side effects. Ischemic optic neuropathy (ION) is "possible" by WHO classification, however, conclusive evidence linking ION to erectile dysfunction medications is still lacking.

UR - http://www.scopus.com/inward/record.url?scp=26844538190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844538190&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2005.02.049

DO - 10.1016/j.ajo.2005.02.049

M3 - Article

C2 - 16226525

AN - SCOPUS:26844538190

VL - 140

SP - 723

EP - 724

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 4

ER -